All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The 60th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from 1–4 December 2018. On Tuesday 4 December 2018, the Late-Breaking Abstracts (LBA) Session took place, during which, Thierry Facon, from the University Hospital of Lille, Lille, France, presented the pre-specified interim analysis of the MAIA clinical trial.
The MAIA study is an international, phase III clinical trial, which examines the efficacy of frontline treatment with the triplet combination of daratumumab, lenalidomide, and dexamethasone (D-Rd) versus (vs) lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for an autologous stem cell transplant (ASCT). Participants were randomized 1:1 to the two treatment arms.
The primary endpoint was progression-free survival (PFS). Key secondary endpoints included: complete response (CR) or better (≥ CR), very good partial response or better (≥ VGPR), minimal residual disease (MRD) negativity rate, overall response rate (ORR), overall survival, and safety. Patients were treated until disease progression (DP) or unacceptable toxicity.
Data are presented as D-Rd vs Rd.
The interim results of the MAIA trial show that the addition of daratumumab in the combination treatment of lenalidomide and dexamethasone reduces the risk of disease progression or death by 44% in patients with NDMM non-eligible for an ASCT. The triplet regimen led to significantly deeper responses and a three-fold higher MRD negativity rate. The safety profile of daratumumab is acceptable and similar to that already described in the POLLUX and ALCYONE trials.
Facon T. et al. Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). 2018 Dec 4; LBA #2: ASH 60th Annual Meeting and Exposition, San Diego, CA.
Subscribe to get the best content related to multiple myeloma delivered to your inbox